Literature DB >> 18443590

Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease.

Jan Monti1, Judith Fischer, Svetlana Paskas, Matthias Heinig, Herbert Schulz, Claudia Gösele, Arnd Heuser, Robert Fischer, Cosima Schmidt, Alexander Schirdewan, Volkmar Gross, Oliver Hummel, Henrike Maatz, Giannino Patone, Kathrin Saar, Martin Vingron, Steven M Weldon, Klaus Lindpaintner, Bruce D Hammock, Klaus Rohde, Rainer Dietz, Stuart A Cook, Wolf-Hagen Schunck, Friedrich C Luft, Norbert Hubner.   

Abstract

We aimed to identify genetic variants associated with heart failure by using a rat model of the human disease. We performed invasive cardiac hemodynamic measurements in F2 crosses between spontaneously hypertensive heart failure (SHHF) rats and reference strains. We combined linkage analyses with genome-wide expression profiling and identified Ephx2 as a heart failure susceptibility gene in SHHF rats. Specifically, we found that cis variation at Ephx2 segregated with heart failure and with increased transcript expression, protein expression and enzyme activity, leading to a more rapid hydrolysis of cardioprotective epoxyeicosatrienoic acids. To confirm our results, we tested the role of Ephx2 in heart failure using knockout mice. Ephx2 gene ablation protected from pressure overload-induced heart failure and cardiac arrhythmias. We further demonstrated differential regulation of EPHX2 in human heart failure, suggesting a cross-species role for Ephx2 in this complex disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443590      PMCID: PMC7370537          DOI: 10.1038/ng.129

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  48 in total

Review 1.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy.

Authors:  J D Molkentin; G W Dorn
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

2.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Authors:  B Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; P O Wester
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

3.  Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group.

Authors:  J B Kostis; B R Davis; J Cutler; R H Grimm; K G Berge; J D Cohen; C R Lacy; H M Perry; M D Blaufox; S Wassertheil-Smoller; H R Black; E Schron; D M Berkson; J D Curb; W M Smith; R McDonald; W B Applegate
Journal:  JAMA       Date:  1997-07-16       Impact factor: 56.272

4.  In silico mapping of complex disease-related traits in mice.

Authors:  A Grupe; S Germer; J Usuka; D Aud; J K Belknap; R F Klein; M K Ahluwalia; R Higuchi; G Peltz
Journal:  Science       Date:  2001-06-08       Impact factor: 47.728

5.  Epidemiology of heart failure.

Authors:  W B Kannel; A J Belanger
Journal:  Am Heart J       Date:  1991-03       Impact factor: 4.749

6.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.

Authors:  Danyan Xu; Ning Li; Yuxia He; Valeriy Timofeyev; Ling Lu; Hsing-Ju Tsai; In-Hae Kim; Dipika Tuteja; Robertino Karlo P Mateo; Anil Singapuri; Benjamin B Davis; Reginald Low; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-27       Impact factor: 11.205

Review 7.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids.

Authors:  Martin Spiecker; James K Liao
Journal:  Arch Biochem Biophys       Date:  2005-01-15       Impact factor: 4.013

8.  Genetics of gene expression surveyed in maize, mouse and man.

Authors:  Eric E Schadt; Stephanie A Monks; Thomas A Drake; Aldons J Lusis; Nam Che; Veronica Colinayo; Thomas G Ruff; Stephen B Milligan; John R Lamb; Guy Cavet; Peter S Linsley; Mao Mao; Roland B Stoughton; Stephen H Friend
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.

Authors:  John Seubert; Baichun Yang; J Alyce Bradbury; Joan Graves; Laura M Degraff; Scott Gabel; Rebecca Gooch; Julie Foley; John Newman; Lan Mao; Howard A Rockman; Bruce D Hammock; Elizabeth Murphy; Darryl C Zeldin
Journal:  Circ Res       Date:  2004-07-15       Impact factor: 17.367

Review 10.  Hypertrophy of the heart: a new therapeutic target?

Authors:  Norbert Frey; Hugo A Katus; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2004-04-06       Impact factor: 29.690

View more
  62 in total

Review 1.  Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.

Authors:  Michel Félétou; Ralf Köhler; Paul M Vanhoutte
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.

Authors:  Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Congest Heart Fail       Date:  2011-01-27

3.  Chiral lipidomics of monoepoxy and monohydroxy metabolites derived from long-chain polyunsaturated fatty acids.

Authors:  Maximilian Blum; Inci Dogan; Mirjam Karber; Michael Rothe; Wolf-Hagen Schunck
Journal:  J Lipid Res       Date:  2018-11-08       Impact factor: 5.922

4.  Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

Authors:  Hsing-Ju Tsai; Sung Hee Hwang; Christophe Morisseau; Jun Yang; Paul D Jones; Takeo Kasagami; In-Hae Kim; Bruce D Hammock
Journal:  Eur J Pharm Sci       Date:  2010-03-30       Impact factor: 4.384

Review 5.  Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Authors:  W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha
Journal:  Neurosci Biobehav Rev       Date:  2018-02-02       Impact factor: 8.989

6.  Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.

Authors:  L Červenka; V Melenovský; Z Husková; A Sporková; M Bürgelová; P Škaroupková; S H Hwang; B D Hammock; J D Imig; J Sadowski
Journal:  Physiol Res       Date:  2015-06-05       Impact factor: 1.881

Review 7.  Emerging directions in the genetics of atrial fibrillation.

Authors:  Nathan R Tucker; Patrick T Ellinor
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 8.  Stress, Genes, and Hypertension. Contribution of the ISIAH Rat Strain Study.

Authors:  Olga E Redina; Arcady L Markel
Journal:  Curr Hypertens Rep       Date:  2018-06-16       Impact factor: 5.369

9.  NADPH Oxidase 4 Regulates Inflammation in Ischemic Heart Failure: Role of Soluble Epoxide Hydrolase.

Authors:  Mark D Stevenson; Chandrika Canugovi; Aleksandr E Vendrov; Takayuki Hayami; Dawn E Bowles; Karl-Heinz Krause; Nageswara R Madamanchi; Marschall S Runge
Journal:  Antioxid Redox Signal       Date:  2018-12-28       Impact factor: 8.401

10.  Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.

Authors:  Ketul R Chaudhary; Mohamed Abukhashim; Sung Hee Hwang; Bruce D Hammock; John M Seubert
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.